Translate

Monday, October 9, 2017

thumbnail

CAPR Capricor Therapeutics, Inc. gains 91% Oct 9, 2017

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials, as well as CAP-1001, which has completed Phase I clinical trial; and CU-NP and CSps. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California. http://www.priceseries.com/trade/CAPR-Capricor-Therapeutics-Inc-stock-gains-91-percent-a-Trade-Record-by-priceSeries-2017091820171009.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive